Most studies have suggested a tumor suppressive role of SSBP2, which is silenced by promoter hypermethylation in several human tumors, including hematologic malignancies, prostate cancer, esophageal squamous cell carcinoma, ovarian cancer, and gallbladder cancer [5–9]. Here, SSBP2 is linked to hematologic disorder.